trial
investig
pathogenet
diagnost
therapeut
aspect
multipl
sclerosi
ms
anim
model
date
back
first
half
centuri
lindsey
fig
loui
pasteur
rabi
vaccin
pasteur
illo
gave
first
hint
possibl
immun
human
xenogen
nervou
tissu
induc
ascend
paralysi
specif
inocul
rabi
patient
desicc
spinal
cord
rabiesinfect
rabbit
caus
pares
limb
neck
facial
muscl
result
gait
swallow
breath
problem
baxter
convers
shown
koritschon
schweinburg
stuart
krikorian
inject
human
spinal
cord
sheep
brain
rabbit
lead
limb
paralysi
clumsi
gait
muscl
weak
river
et
al
first
demonstr
monkey
immun
rabbit
brain
brain
extract
paralysi
associ
perivascular
infiltr
demyelin
brain
spinal
cord
call
diseas
acut
dissemin
encephalomyel
term
later
chang
experiment
allerg
autoimmun
encephalomyel
eae
sinc
frequenc
sever
paralys
correl
titer
antibrain
antibodi
research
subsequ
trial
boost
humor
immun
respons
freund
adjuv
cfa
freund
mcdermott
later
complement
pertussi
toxin
munoz
et
al
therebi
could
induc
oscillatori
symptom
relapsingremit
cours
diseas
accompani
perivascular
leukocyt
infiltr
acut
lesion
gliosi
chronic
lesion
reminisc
ms
patholog
experi
perform
first
guinea
pig
freund
et
al
monkey
morgan
wolf
et
al
later
variou
speci
includ
mice
olitzki
yager
rat
lipton
freund
enabl
extens
immunogenet
histopatholog
therapeut
studi
turn
histopatholog
clinic
cours
diseas
vari
significantli
reflect
part
heterogen
human
counterpart
depend
genet
background
anim
sourc
antigen
materi
mode
applic
antigen
olsson
et
al
wekerl
et
al
importantli
stepwis
reduct
complex
antigen
materi
crude
brain
tissu
protein
extract
variou
central
myelin
protein
myelin
basic
protein
mbp
einstein
et
al
laatsch
et
al
ii
myelin
oligodendrocyt
odc
glycoprotein
mog
lebar
et
al
iii
proteolipid
protein
plp
tuohi
et
al
iv
myelinassoci
oligodendrocyt
basic
protein
nucleotid
phosphodiesteras
et
al
small
encephalitogen
peptid
eylar
et
al
lennon
et
al
mbp
mbp
mbp
mbp
mog
plp
reproduc
eae
model
becam
avail
mirror
differ
featur
ms
wekerl
et
al
recent
varieti
addit
antigen
suppos
involv
autoimmun
reaction
ms
eae
tabl
myelin
constitu
neurofascin
nf
mathey
et
al
other
express
myelin
axon
axon
derfuss
et
al
entir
nonmyelin
antigen
neuron
membran
protein
neurofascin
nf
mathey
et
al
neuron
cytoskelet
protein
neurofilamentm
astrocytetyp
ca
bind
protein
kojima
et
al
neurofascin
nf
nf
adhes
molecul
identifi
put
ms
autoantigen
proteomicsbas
screen
approach
ms
sera
subsequ
shown
promot
autoimmun
pathogenesi
eae
rat
model
derfuss
et
al
derfuss
et
al
mathey
et
al
antibodi
neurofascin
particular
nf
caus
axon
injuri
without
enhanc
inflamm
demyelin
mogea
mathey
et
al
contrast
mogea
cell
induc
inflammatori
lesion
preferenti
cerebr
cortex
spinal
cord
white
gray
matter
derfuss
et
al
howev
cell
unabl
caus
demyelin
open
bloodbrain
barrier
bbb
therebi
allow
access
antimog
antibodi
central
nervou
system
cn
could
trigger
demyelin
eae
variant
induc
axon
antigen
may
reflect
special
featur
ms
subtyp
eg
character
cortic
lesion
histolog
pattern
ii
iv
accord
classif
lucchinetti
et
al
schemat
draw
fig
indic
molecular
localis
current
known
put
autoantigen
eae
protein
glycoprotein
lipoprotein
possess
encephalitogen
epitop
may
expos
outer
surfac
odc
myelin
may
resid
compact
myelin
zone
myelinaxon
interfac
node
ranvier
last
localis
three
adhes
molecul
nf
nf
differenti
express
wherea
nf
localis
paranod
myelin
loop
interact
contactinassoci
protein
caspr
axoplasm
ternari
complex
charl
et
al
nf
expos
nonmyelin
part
node
ranvier
interact
neurongliarel
cell
adhes
molecul
nrcam
voltageg
na
channel
hedstrom
et
al
also
express
juxtaparanod
myelin
axon
membran
form
dimer
molecular
zipper
rtl
et
al
shimoda
watanab
whether
lipid
glycolipid
phospholipid
play
also
role
autoantigen
eae
ms
clear
although
sever
evid
experiment
clinic
studi
support
role
podbielska
hogan
candiat
myelin
lipid
autoantigen
ms
andor
eae
shown
tabl
lipid
microarray
studi
kanter
et
al
coimmun
sulfatid
coapplic
sulfatidespecif
antibodi
worsen
clinic
cours
plp
eae
sjlj
mice
quintana
et
al
found
autoantibodi
lipid
oxid
cholesterol
deriv
serum
ms
patient
immunopatholog
pattern
ii
accord
lucchinetti
et
al
howev
oxid
cholesterol
deriv
affect
specif
humor
cell
respons
mog
eae
sever
studi
shown
activ
induc
eae
model
reproduc
typic
tempor
matur
ms
lesion
inflamm
without
deposit
immunoglobulin
demyelin
axon
damag
gliosi
partial
remyelin
howev
special
phenotyp
ms
patholog
primari
neuron
degener
shift
helper
cell
cytotox
cell
lesion
cortic
area
rare
reproduc
activ
induc
eae
model
akta
et
al
gold
et
al
herreroherranz
et
al
linker
et
al
pomeroy
et
al
hitherto
clear
extent
cortic
lesion
account
brain
atrophi
ms
merkler
et
al
could
induc
focal
demyelin
lesion
cortex
mogea
rat
stereotact
inject
proinflammatori
cytokin
tumor
necrosi
factora
tnfa
interferong
ifng
correspond
find
ms
focal
cortic
lesion
rapidli
remyelin
accordingli
marmoset
mogea
focal
cortic
lesion
major
caus
diffus
cortic
atrophi
pomeroy
et
al
potenti
pathomechan
cn
atrophi
ms
complex
may
includ
sever
mechan
neuron
damag
anterograd
wallerian
degener
neuron
dyingback
neuron
soma
dendrit
shrinkag
dziedzic
et
al
siffrin
et
al
current
disclosur
exact
mechan
axon
damag
major
challeng
ms
research
sinc
appear
main
caus
clinic
disabl
may
result
immun
andor
nonimmun
attack
neuron
rather
consequ
immunemedi
demyelin
siffrin
et
al
concern
aetiopathogenesi
ms
role
infect
still
matter
controversi
mice
lymphocyt
choriomenig
viru
protein
express
could
elicit
chronic
autoimmun
inflamm
demyelin
cn
evan
et
al
chlamydia
pneumoniaspecif
peptid
share
immunodomin
epitop
mbpinduc
sever
clinic
histolog
eae
lenz
et
al
wherea
intestin
parasit
convey
resist
eae
eaesuscept
lewi
rat
zorzella
et
al
also
human
herp
viru
type
epsteinbarr
viru
measl
viru
retrovirus
implic
aetiopathogenesi
ms
current
avail
experiment
clinic
data
convinc
enough
justifi
antivir
antibiot
therapi
ms
howev
experiment
demyelin
diseas
induc
theiler
viru
theiler
ure
rodriguez
coronaviru
lavi
canin
distemp
viru
seehusen
rtner
suitabl
model
investig
aspect
ms
patholog
increas
antibodi
serum
cerebrospin
fluid
patient
ms
optic
neuriti
et
al
lactosylceramid
lalysophosphatidylserin
strong
antibodi
reactiv
serum
cerebrospin
fluid
ms
patient
kanter
et
al
quintana
et
al
mileston
develop
increasingli
specif
eae
model
fig
induct
eae
transfer
total
lymph
node
cell
paterson
isol
mbpspecif
celllin
cell
bennun
et
al
depend
plpspecif
helper
cell
langrish
et
al
naiv
rat
mice
respect
establish
distinct
form
adopt
transfer
eae
atea
ii
gener
transgen
mice
delet
knockout
lead
lossoffunct
overexpress
knockin
lead
gain
function
pathogenet
relev
gene
review
krishnamoorthi
et
al
exampl
gene
encod
cell
receptor
tcr
bettelli
et
al
goverman
et
al
lafail
et
al
mendel
et
al
major
histocompat
complex
mhc
molecul
fries
et
al
khare
et
al
linker
et
al
mangalam
et
al
cytokin
review
campbel
et
al
owen
et
al
well
neurotroph
factor
linker
et
al
linker
et
al
linker
et
al
mirowskaguzel
receptor
dallenga
et
al
linker
et
al
constitut
knockout
knockin
cytokin
gene
throughout
whole
develop
adulthood
anim
impli
seriou
drawback
due
redund
feedback
loop
cytokin
signal
pathway
owen
et
al
steinman
constraint
overcom
approach
induc
spatial
tempor
restrict
gene
target
recent
introduc
studi
direct
cn
riaux
ruff
kieffer
velmey
et
al
despit
obviou
import
autoimmun
process
pathogenesi
ms
evid
nonimmun
origin
least
subtyp
ms
exampl
even
aggress
immunosuppress
suffici
treat
progress
ms
therefor
addit
experiment
model
need
especi
studi
nonimmunemedi
demyelin
axon
loss
via
odc
degener
purpos
toxic
model
demyelin
develop
base
select
toxic
odc
copper
chelat
biscyclohexanon
oxaldihydrazon
cuprizon
blakemor
carlton
young
mice
fed
cuprizon
focal
demyelin
occur
predominantli
cerebellar
cortex
peduncl
withdraw
toxin
spontan
remyelin
seen
predominantli
rostral
region
skripuletz
et
al
torkildsen
et
al
therebi
cuprizonemodel
correl
well
histopatholog
featur
ms
especi
subtyp
variant
classifi
histolog
pattern
iii
accord
lucchinetti
et
al
render
use
tool
ms
research
einstein
et
al
kipp
et
al
paradox
accord
recent
report
herder
et
al
cuprizon
amelior
theiler
murin
encephalomyel
suggest
might
immunomodulatori
andor
antivir
properti
addit
toxic
effect
f
g
f
g
fig
put
autoantigen
eae
indic
preferenti
localis
inset
refer
odc
membran
inset
myelin
surfac
zone
inset
compact
myelin
zone
inset
myelinaxon
interfac
zone
inset
nodal
paranod
zone
node
ranvier
inset
abbrevi
cnp
cyclic
cyt
cytoplasm
ext
extracellular
space
mag
myelinassoci
glycoprotein
mbp
myelin
basic
protein
mog
myelin
oligodendrocyt
glycoprotein
nf
neurofascin
plp
proteolipid
protein
tag
transient
axon
glycoprotein
current
common
mode
eae
induct
base
inject
encephalitogen
peptid
mostli
mog
plp
emulsifi
cfa
contain
miner
oil
mycobacterium
tuberculosi
strain
follow
intraperiton
inject
pertussi
toxin
fig
result
phenotyp
depend
mainli
antigen
sourc
genet
background
anim
speci
strain
use
exampl
plp
induc
relapsingremit
eae
sjl
mice
wherea
mog
trigger
chronicprogress
eae
mice
favor
mice
transgen
experi
cross
mice
overexpress
mogtcr
mogspecif
b
cell
result
sever
form
eae
close
replic
devic
variant
ms
inflammatori
lesion
optic
nerv
spinal
cord
bettelli
et
al
mogtcr
transgen
mice
backcross
sjlj
background
develop
relapsingremit
form
eae
episod
alter
optic
nerv
cerebellum
spinal
cord
evolut
model
depend
intact
b
cell
compart
appar
mogtcr
transgen
cell
expand
endogen
autoreact
b
cell
manufactur
pathogen
demyelin
autoantibodi
conform
epitop
nativ
mog
protein
whilst
recogn
cell
target
mog
peptid
llinger
et
al
author
claim
gener
first
spontan
anim
model
relapsingremit
ms
current
type
atea
includ
induc
cell
suggest
newli
detect
effector
cell
may
part
respons
patholog
heterogen
ms
lesion
afzali
et
al
gold
hder
hofstett
et
al
hofstett
et
al
ger
et
al
korn
et
al
quintana
et
al
reboldi
et
al
eae
model
directli
access
investig
immun
nervou
system
fig
interact
pathogenesi
diseas
target
establish
experiment
therapi
sinc
ms
appear
polygenet
determin
diseas
effort
undertaken
linkag
associ
studi
defin
chromosom
region
quantit
trait
loci
qtl
control
suscept
diseas
compar
qtl
suscept
loci
anim
model
eae
ndez
et
al
high
frequenc
intergenom
eaem
consensu
gene
support
valu
eae
studi
ms
featur
backcross
offspringpar
mate
intercross
sibl
mate
experi
eae
suscept
resist
anim
strain
mice
rat
guinea
pig
hamster
reveal
mainli
mhclink
qtl
encina
et
al
olsson
et
al
combinedcross
analysi
could
enhanc
detect
qtl
moder
effect
rat
jagod
olsson
genotyp
microsatellit
marker
intercross
popul
eaesuscept
sjll
mice
eaeresist
mice
identifi
qtl
link
increas
latenc
cortic
motor
evok
potenti
nonimmun
anim
correl
earlier
onset
diseas
n
ez
et
al
find
point
role
myelin
composit
synapt
transmiss
suscept
eae
provid
chanc
detect
individu
high
risk
autoimmun
demyelin
qtl
analysi
diseas
manifest
ms
immun
responserel
gene
identifi
genomewid
associ
studi
use
singl
nucleotid
polymorph
analysi
microarray
techniqu
herit
risk
factor
diseas
although
individu
contribut
clearli
modest
odd
ratio
exceed
imsgc
gene
includ
interleukin
il
receptor
gene
chromosom
respect
human
leukocyt
antigen
hla
belong
mhc
class
ii
molecul
chromosom
tabl
imsgc
recent
gene
encod
follow
protein
confirm
novel
ms
risk
gene
explan
abbrevi
tabl
dabbeekeh
et
al
de
jager
et
al
b
hafler
et
al
hoppenbrouw
et
al
hoppenbrouw
et
al
imsgc
johnson
et
al
mero
et
al
rubio
et
al
sarria
et
al
strongest
associ
ms
suscept
although
age
onset
sever
diseas
found
allel
barcello
et
al
chao
et
al
wherea
transgen
mice
overexpress
human
allel
develop
sever
mogea
khare
et
al
contrast
gene
relat
antigen
process
also
slow
diseas
progress
reflect
milder
cours
diseas
mog
eae
congen
norltj
mice
compar
wildtyp
nod
mice
mayo
quinn
similarli
congen
map
rat
genom
confirm
chromosom
region
homolog
human
ms
suscept
region
confer
protect
mogea
jagod
et
al
also
transgen
mog
eae
mice
overexpress
tcr
mog
show
protect
rather
pathogen
effect
mendel
et
al
contrast
transgen
mice
overexpress
mbpspecif
tcr
develop
high
frequenc
spontan
eae
goverman
et
al
lafail
et
al
relev
find
human
diseas
remain
elucid
research
eae
also
yield
hint
exist
chromosom
loci
control
diseas
suscept
depend
age
season
point
role
chronobiolog
autoimmun
teuscher
et
al
moreov
eae
suscept
vari
even
differ
coloni
anim
strain
demonstr
lewi
rat
purchas
differ
anim
facil
gould
et
al
sinc
genet
background
anim
almost
ident
mechan
preferenti
involv
gene
regul
may
respons
differ
diseas
suscept
progress
transcriptom
proteom
analys
power
new
tool
elucid
mechan
fernald
et
al
goertsch
zettl
ibrahim
et
al
ibrahim
gold
integr
analysi
avail
data
genomewid
genet
screen
highthroughput
gene
express
studi
ms
eae
reveal
differenti
express
gene
appear
mainli
cluster
rather
uniform
distribut
throughout
genom
fernald
et
al
herebi
includ
hypothesisneutr
gene
express
studi
mainli
perform
microarray
techniqu
rna
profil
appli
ms
patient
peripher
blood
mononuclear
cell
brain
tissu
eae
anim
lymphat
nervou
tissu
tajouri
et
al
deliv
increas
wealth
data
impli
great
challeng
bioinformat
analysi
may
includ
pathway
analys
use
background
inform
gene
ontolog
project
data
base
well
data
mine
approach
result
gene
express
studi
gener
hamper
method
problem
heterogen
materi
differ
individu
difficulti
defin
reason
threshold
differenti
express
gene
nevertheless
meaning
data
alreadi
obtain
express
studi
eae
point
new
eaeqtl
suscept
gene
dissect
new
pathogen
protect
pathway
identifi
new
therapeut
target
comabella
martin
jelinski
et
al
matejuk
et
al
n
ez
et
al
mix
et
al
mix
et
al
paintlia
et
al
exampl
comparison
eaeresist
strain
eaesuscept
strain
mog
eae
model
strongli
support
eaeresist
activ
process
reveal
new
target
gene
therapeut
intervent
mix
et
al
moreov
data
baranzini
et
al
deriv
mog
eae
model
led
new
conclus
earli
nonspecif
bbb
impair
mainli
neutrophilrel
secondari
immun
cfa
ii
transit
innat
adapt
immun
respons
onset
eae
iii
identif
least
discret
eae
phase
earli
eae
peak
eae
earli
recoveri
characterist
gene
express
pattern
iv
earli
neuron
damag
therefor
gene
express
studi
provid
new
insight
dynam
discret
earli
progress
phase
eae
transcript
level
consist
histolog
clinic
phenotyp
serv
tool
fingerprint
individu
diseas
process
man
practic
consequ
new
therapeut
target
surfac
rna
profil
also
enabl
research
identifi
gene
support
mainten
hematopoiet
stem
cell
nich
synaps
sourc
therapeut
mesenchym
stem
cell
amelior
eae
pedemont
et
al
hand
eae
also
serv
tool
valid
new
target
deriv
genemicroarray
analysi
lock
et
al
despit
clear
benefit
transcriptom
approach
voic
advis
caution
concern
overinterpret
result
global
gene
express
analysi
case
due
obviou
limit
transcriptom
employ
clear
specif
question
mind
care
view
regulatori
set
potenti
pitfal
techniqu
casciano
woodcock
fathallahshaykh
true
proteom
approach
review
elkab
li
linker
et
al
eae
serv
gener
differenti
protein
tabl
suscept
gene
ms
function
refer
antigen
present
barcello
et
al
chao
et
al
imsgc
ribosom
protein
transport
nonribosomeassoci
cytoplasm
rrna
nucleolu
assembl
ribosom
rubio
et
al
express
profil
duzhak
et
al
liu
et
al
monitor
divers
autoantibodi
respons
robinson
et
al
valid
new
therapeut
target
deriv
lasercaptur
microdissect
ms
lesion
han
et
al
also
put
lipid
autoantigen
could
identifi
microarray
approach
ms
eae
kanter
et
al
quintana
et
al
still
consensu
amongst
research
immunolog
process
play
pivot
role
pathogenesi
progress
ms
linker
et
al
steinman
zamvil
weiner
although
aetiolog
factor
may
vari
differ
subtyp
ms
may
primarili
affect
immun
system
especi
case
histopatholog
pattern
iii
iv
accord
lucchinetti
et
al
moreov
earli
ms
histolog
pattern
iiii
wallerian
degener
seem
contribut
significantli
axon
loss
plaqu
periplaqu
white
matter
dziedzic
et
al
current
concept
pathogenet
process
ms
schemat
depict
fig
indic
also
therapeut
intervent
put
target
recent
paradigm
shift
relat
recognit
new
role
cell
fries
fugger
b
cell
franciotta
et
al
innat
immun
weiner
emerg
pathogen
pathway
caus
neuron
damag
centonz
et
al
dziedzic
et
al
herz
et
al
eae
model
consider
contribut
understand
immun
regulatori
process
pathogenesi
ms
wekerl
et
al
tradit
regulatori
suppress
activ
autoimmun
process
primarili
attribut
cell
recent
regulatori
cell
yi
et
al
attract
interest
respect
ephrem
et
al
paintlia
et
al
tischner
et
al
seem
import
antagonist
cell
afzali
et
al
littman
rudenski
quintana
et
al
suppos
effector
cell
eae
hofstett
et
al
huppert
et
al
liu
et
al
steinman
ms
gold
hder
howev
pathogen
role
cell
eae
controversi
accord
find
haak
et
al
transgen
mice
vivo
function
cn
may
redund
member
famili
may
contribut
margin
autoimmun
pathogenesi
mog
eae
hand
huppert
et
al
found
promot
breakdown
bbb
crucial
step
develop
eae
moreov
find
nowak
et
al
point
proinflammatori
role
mog
eae
cell
driven
korn
et
al
langrish
et
al
mckenzi
et
al
suppress
fitzgerald
et
al
wang
et
al
recent
pathway
implic
surviv
expans
effectormemori
cell
blockad
render
differenti
cell
suscept
apoptosi
led
attenu
mogea
correspond
tc
cell
show
impair
cytotox
ifng
product
may
excess
product
contribut
inflammatori
process
eae
ms
huber
et
al
recent
sobottka
et
al
could
demonstr
brain
slice
transgen
mice
myelindirect
tc
cell
caus
extens
damag
myelin
sheath
also
axon
consequ
cell
may
contribut
axon
loss
eae
probabl
also
ms
immunopatholog
pattern
accord
lucchinetti
et
al
b
cell
involv
immunopathogenesi
ms
eae
least
two
function
activ
ie
antigenpres
cell
f
g
f
g
fig
put
pathogen
mechan
ms
autoreact
lymphocyt
may
recruit
peripher
lymphoid
organ
migrat
bbb
reactiv
cn
inflammatori
cascad
initi
lead
subsequ
damag
myelin
axon
altern
primari
oligodendrogli
axon
degener
may
follow
inflammatori
autoimmun
process
adjac
tabl
depict
put
pathogen
process
target
establish
experiment
therapi
treatment
group
accord
contribut
made
eae
develop
ie
either
success
translat
clinic
green
success
eae
red
current
test
eae
andor
ms
yellow
abbrevi
aicar
apc
antigenpres
cell
apl
alter
peptid
ligand
bbb
bloodbrain
barrier
bdnf
brainderiv
neurotroph
factor
cd
cluster
differenti
cn
central
nervou
system
cntf
ciliari
neurotroph
factor
cryab
abcrystallin
cyla
calpain
inhibitor
n
dimethoxycinnamoyl
anthranil
acid
dopamin
receptor
type
egcg
il
interleukin
ifng
interferong
major
histocompat
complex
mog
myelin
oligodendrocyt
glycoprotein
mp
methylprednisolon
mri
magnet
reson
imag
nk
natur
killer
odc
oligodendrocyt
plp
proteolipid
protein
ppara
peroxisom
proliferatoractiv
receptora
ssri
select
serotonin
reuptak
inhibitor
tc
cytotox
cell
tcr
cell
receptor
tgfb
transform
growth
factorb
th
cell
helper
cell
tnfa
tumor
necrosi
factora
apc
antibodi
produc
franciotta
et
al
goverman
hohlfeld
et
al
martin
mdel
monson
weiner
ziemssen
ziemssen
addit
may
costimul
cell
facilit
recruit
inflammatori
cell
cn
myelin
opson
also
promot
remyelin
take
part
immunoregulatori
process
antimyelin
antibodi
suppos
major
compon
histopatholog
ms
pattern
ii
accord
lucchinetti
et
al
special
role
target
antibodi
distinct
type
eae
ms
ascrib
myelin
molecul
mog
haas
et
al
axon
molecul
neurofascin
hohlfeld
et
al
anoth
distinct
lymphocyt
subpopul
implic
cn
autoimmun
gd
cell
subset
bear
tcrgd
fetaltyp
cell
increas
number
ms
cerebrospin
fluid
mix
et
al
may
exert
pathogen
regulatori
function
review
blink
goverman
interestingli
major
produc
host
cell
atea
belong
gd
cell
type
lee
et
al
ad
complex
obviou
pathogen
role
eae
ms
innat
immun
mediat
dendrit
cell
monocyt
microglia
furtado
et
al
wherea
adapt
immun
system
seem
drive
mainli
relaps
ms
abnorm
innat
immun
system
may
prevail
progress
stage
diseas
weiner
import
aspect
ms
pathogenesi
apoptot
activ
lymphat
nervou
system
therefor
apoptot
process
analys
eae
apoptosi
play
obvious
pivot
pathogen
role
affect
odc
velmey
et
al
appear
protect
elimin
myelinreact
bystand
cell
zettl
et
al
process
augment
therapeut
drug
methylprednisolon
mp
schmidt
et
al
resveratrol
singh
et
al
role
cytokin
neurotroph
factor
pathogenesi
ms
eae
investig
plethora
studi
result
review
elsewher
goverman
imitola
et
al
link
linker
et
al
mirowskaguzel
owen
et
al
ozenc
et
al
detail
reader
refer
review
addit
mention
immunopathogen
pathway
direct
crosstalk
immun
nervou
system
may
influenc
pathogenesi
ms
eae
kerschenstein
et
al
mix
et
al
involv
direct
effect
cytokin
chemokin
nerv
cell
modul
immun
cell
activ
neurotrophin
neurotransmitt
implic
new
treatment
approach
eg
associ
condit
disclosur
complex
mechan
neuroimmun
interact
requir
investig
eae
model
mani
aspect
ms
research
investig
anim
model
among
monitor
diseas
activ
tradit
magnet
reson
imag
mri
morrissey
et
al
new
bioluminesc
techniqu
luo
et
al
deserv
special
attent
identif
reliabl
surrog
marker
diagnost
prognost
purpos
respond
detect
specif
therapi
diseas
followup
promin
task
futur
howev
consist
limit
translat
experiment
result
clinic
differ
situat
eae
ms
concern
timelin
detect
clinic
sign
therapeut
intervent
fig
wherea
eae
patholog
process
observ
begin
treatment
approach
start
earli
preclin
phase
ms
diagnost
measur
commonli
initi
first
clinic
sign
present
intens
treatment
increas
usual
late
progress
diseas
despit
extens
screen
new
target
ms
therapi
eae
far
establish
ms
therapi
develop
anim
model
exampl
glatiram
acet
mitoxantron
natalizumab
kieseier
hartung
steinman
zamvil
glatiram
acet
prepar
random
polym
consist
repeat
sequenc
four
amino
acid
glutam
acid
lysin
alanin
tyrosin
occur
mbp
specif
molar
ratio
primarili
call
copolym
test
first
encephalitogen
potenc
subsequ
influenc
guinea
pig
eae
teitelbaum
et
al
surprisingli
turn
copolym
suppress
rather
induc
eae
probabl
via
stimul
antimbp
immun
respons
aharoni
et
al
aharoni
et
al
recent
studi
utilis
sophist
immunolog
techniqu
point
complex
mechan
action
glatiram
acet
includ
modif
kill
apc
gener
regulatori
cell
turn
polyclon
cell
respons
oligoclon
one
mitoxantron
first
proven
power
immunosuppress
drug
eae
ridg
et
al
secondlin
compon
escal
ms
therapi
hartung
et
al
krapf
et
al
neuhau
et
al
b
rieckmann
et
al
mechan
action
reli
probabl
cytotox
effect
lymphocyt
induct
apoptosi
apc
monocyt
dendrit
cell
neuhau
et
al
vollmer
et
al
natalizumab
monoclon
antibodi
mab
inhibit
transmigr
immun
cell
inflam
parenchyma
lymphat
organ
cn
bind
late
activ
lymphocyt
block
interact
integrin
ligand
vascular
cell
adhes
endothelia
cell
therebi
effect
prevent
eae
rice
et
al
yednock
et
al
first
mab
approv
therapeut
trial
ms
polman
et
al
belong
secondlin
ms
therapeut
although
carri
risk
activ
polyoma
viru
jc
lead
progress
multifoc
leukoencephalopathi
especi
appli
combin
ifnb
clifford
et
al
kleinschmidtdemast
tyler
langergould
et
al
bennett
yousri
et
al
recent
even
case
progress
multifoc
leukoencephalopathi
natalizumab
monotherapi
report
clifford
et
al
hartung
hartung
et
al
et
al
wen
et
al
number
establish
ms
therapi
subsequ
investig
eae
model
aim
get
deeper
insight
mechan
action
includ
disclosur
specif
target
therapi
ii
improv
regimen
old
therapi
develop
new
therapi
target
pathogen
mechan
conveni
clinic
practic
low
frequenc
applic
oral
applic
avoid
advers
sideeffect
exampl
respect
methylprednisolon
therapi
ms
relaps
schmidt
et
al
could
unravel
switch
cytoplasm
nuclear
effect
accompani
enhanc
cell
apoptosi
increas
steroid
dosag
moreov
liposom
encapsul
mp
reveal
dosedepend
increas
therapeut
effici
compar
free
mp
eae
linker
et
al
ifnb
treat
eae
interrupt
therapi
caus
diseas
exacerb
van
der
meid
et
al
attempt
explor
influenc
intraven
immunoglobulin
ivig
therapi
local
immun
respons
cn
et
al
found
accumul
ivig
activ
cn
lesion
bbb
breakdown
limit
prospect
repair
process
howev
natur
regulatori
cell
enhanc
prophylact
applic
ivig
eae
studi
ephrem
et
al
suggest
potenti
benefit
therapi
earli
onset
ms
therapeut
trial
two
treatment
combin
order
achiev
synergist
effect
andor
reduc
advers
sideeffect
singl
agent
exampl
combin
applic
mp
erythropoietin
protect
neuron
axon
retin
ganglion
cell
optic
nerv
rat
moginduc
eae
morpholog
function
impair
wherea
monotherapi
caus
isol
neuron
axon
protect
without
clinic
benefit
diem
et
al
mbpinduc
activ
rat
eae
model
antiinflammatori
antidemyelin
neuroprotect
effect
coenzym
reductas
inhibitori
statin
could
improv
combin
select
inhibitor
rolipram
paintlia
et
al
paintlia
et
al
protein
kinas
activ
substanc
paintlia
et
al
even
statin
appli
suboptim
dose
rolipram
alon
benefici
effect
anim
model
could
previous
reproduc
human
system
zhu
et
al
activ
induc
chronic
murin
eae
synergist
therapeut
effect
ifnb
immunomodulatori
drug
laquinimod
observ
et
al
patient
studi
ifnbmedi
upregul
antiinflammatori
cytokin
enhanc
addit
administr
nonselect
phosphodiesteras
inhibitor
pentoxiphyllin
weber
et
al
pentoxiphyllin
also
reduc
sideeffect
ifnb
therapi
myalgia
fever
inject
site
reaction
rieckmann
et
al
ivig
decreas
cell
apoptosi
liver
damag
increas
odc
apoptosi
highdos
mbptreat
rat
atea
induc
mbpspecif
cell
weishaupt
et
al
also
peril
combin
effect
alway
foreseen
therebi
prevent
anim
model
illustr
hazard
combin
ifnb
natalizumab
kleinschmidtdemast
tyler
langergould
et
al
bennett
statin
birnbaum
et
al
diseasemodifi
agent
act
larg
modul
peripher
immun
mechan
appear
act
addit
even
predominantli
local
within
cn
eg
bbb
like
ifnb
dhibjalbut
mark
natalizumab
rice
et
al
resid
autoreact
cell
odc
like
fingolimod
miron
et
al
miron
et
al
papadopoulo
et
al
enter
cn
via
local
disrupt
bbb
lesion
site
ifnb
may
also
directli
act
astrocyt
boutro
et
al
microglia
prinz
et
al
even
exert
direct
protect
effect
neuron
pliopli
massimini
hand
sever
exampl
compound
quit
effect
curtail
diseas
activ
anim
model
turn
lack
therapeut
util
prove
gener
inaccept
advers
effect
ms
patient
inconsist
prompt
sriram
steiner
consid
eae
mislead
model
ms
exampl
therapi
failur
ms
given
tabl
reason
discrep
result
obtain
anim
human
system
could
manifold
natur
may
genet
speci
differ
peculiar
inbr
anim
strain
pathogenet
individu
variabl
ms
patient
kinet
differ
ontogeni
biorhythm
tempor
differ
immun
reactiv
respons
therapi
addit
ms
bbb
may
insuffici
disrupt
compar
eae
therebi
prevent
therapeut
molecul
reach
target
within
cn
seem
relev
especi
target
cytokin
ms
exampl
mab
ustekinumab
fail
improv
relapsingremit
ms
despit
promis
result
rodent
marmoset
eae
segal
et
al
review
steinman
promis
therapeut
principl
reveal
alreadi
anim
model
limit
benefit
advers
effect
preclud
use
ms
therapeut
exampl
neuroprotect
polypeptid
hormon
ciliari
neurotroph
factor
cntf
elicit
acutephas
respons
rat
liver
dittrich
et
al
ii
antiadhes
molecul
mab
reveal
mri
effect
atea
morrissey
et
al
iii
na
channel
blocker
phenytoin
potenti
protect
demyelin
axon
result
exacerb
mogea
withdraw
black
et
al
iv
inhibitor
rolipram
effect
suppress
eae
fail
suppress
inflammatori
activ
glean
magnet
reson
imag
pilot
trial
patient
relapsingremit
ms
bielekova
et
al
v
immunosuppress
drug
cyclosporin
prevent
bbb
disrupt
suppress
develop
eae
classifi
unaccept
treatment
ms
base
riskbenefit
consider
due
low
efficaci
frequent
advers
reaction
goodin
et
al
kappo
et
al
kieseier
hartung
mccomb
et
al
paul
bolton
one
therefor
consid
therapeut
trial
conduct
eae
translat
clinic
may
well
regard
mislead
model
ms
howev
sever
aspect
aetiopathogenesi
ms
suscept
gene
immunoregulatori
circuit
mechan
immun
cell
activ
migrat
elimin
well
nervou
tissu
destruct
repair
success
studi
eae
render
use
model
ms
hemmer
hartung
schreiner
et
al
eae
continu
util
futur
one
capit
avail
distinct
type
eae
includ
induc
transgen
knockout
anim
explor
pathogen
pathway
strategi
intervent
differ
subtyp
variant
ms
outlin
sever
therapeut
intervent
success
exclus
eae
ms
therapeut
agent
shown
proven
benefit
eae
ms
survey
agent
given
tabl
also
instanc
therapeut
agent
treatment
ms
clinic
develop
without
prior
evalu
anim
model
exampl
drug
includ
propos
mechan
action
list
tabl
nonetheless
increas
number
emerg
therapi
ms
current
test
preclin
phase
make
use
eae
model
cohen
rieckmann
linker
et
al
weiner
promis
experiment
therapi
reli
gene
transfer
stem
cell
transplant
oral
administr
small
molecular
weight
diseasemodifi
drug
intraven
subcutan
applic
mab
target
cell
molecul
crucial
pathogenesi
diseas
bielekova
becker
butti
et
al
einstein
et
al
hauser
et
al
hawker
et
al
hemmer
hartung
kieseier
wiendl
pluchino
martino
wynn
et
al
tabl
provid
survey
experiment
therapeut
approach
current
investig
alreadi
approv
phase
iiii
clinic
trial
tabl
also
includ
propos
mechan
action
new
therapi
put
target
establish
experiment
ms
therapi
without
prior
test
eae
indic
fig
experiment
approach
ms
base
vaccin
eg
pathogen
cell
tcr
dendrit
cell
puls
antigen
dna
vaccin
encod
mbp
axon
growth
inhibitor
associ
myelin
proinflammatori
cytokin
approach
extens
review
elsewher
correal
et
al
recent
new
therapeut
target
select
treatment
eae
ms
compar
avail
therapi
propos
ie
pathway
affect
pathogen
cell
spare
regulatori
cell
unrel
immun
cell
import
field
therapeut
approach
eae
ms
deserv
attent
futur
enhanc
remyelin
far
experiment
trial
involv
transplant
neural
stem
cell
odc
precursor
cell
schwann
cell
olfactori
ensheath
cell
applic
growth
factor
platelet
deriv
growth
factor
epiderm
growth
factor
franklin
ffrenchconst
howev
trial
hamper
fact
demyelin
tabl
therapeut
agent
effect
ms
eae
clinic
isol
syndrom
ci
ms
eae
azathioprin
yudkin
et
al
et
al
rosenthal
gluckman
comi
et
al
comi
et
al
kieseier
hartung
aharoni
et
al
rack
et
al
teitelbaum
et
al
ifnb
comi
et
al
jacob
et
al
kappo
et
al
kappo
lindberg
kieseier
hartung
marri
cohen
dhibjalbut
mark
ruul
et
al
laquinimod
comi
et
al
brunmark
et
al
sipe
et
al
tabl
reproduc
mix
et
al
slight
modif
permiss
publish
springer
egcg
green
tea
constitu
block
proteasom
complex
prolifer
tnfa
product
encephalitogen
cell
format
neurotox
reactiv
oxygen
speci
akta
et
al
lesion
regularli
widespread
dispers
within
cn
addit
lack
stimul
factor
odc
precursor
cell
recruit
differenti
even
contain
inhibitori
factor
remyelin
like
neurit
outgrowth
inhibitora
nogoa
receptor
compon
leucinrich
repeat
ig
domain
pernet
et
al
therefor
current
effort
enhanc
remyelin
eae
ms
reli
mainli
establish
therapi
remyelin
potenc
ivig
especi
polyclon
igm
bieber
et
al
trebst
stangel
wright
et
al
glatiram
acet
aharoni
et
al
arnon
aharoni
rack
et
al
fingolimod
miron
et
al
miron
et
al
applic
antagonist
remyelin
inhibitor
nogoa
bourquin
et
al
mi
et
al
mi
et
al
rudick
et
al
yang
et
al
review
restrict
eae
model
ms
short
refer
toxic
cuprizonemedi
model
demyelin
inform
advantag
disadvantag
eae
addit
virusmedi
demyelin
diseas
deriv
excel
monograph
experiment
model
multipl
sclerosi
edit
lavi
constantinescu
summari
specif
question
ms
genet
pathogenesi
therapi
requir
investig
differ
avail
forthcom
eae
model
comparison
import
immunopatholog
clinic
therapeut
featur
eae
ms
given
tabl
therebi
becom
obviou
great
precaut
advis
translat
result
experiment
therapeut
trial
clinic
practic
eilhard
mix
han
meyerrieneck
hanspet
hartung
uwe
k
zettl
conflict
interest
relat
review
declar
therapeut
approach
propos
mechan
action
refer
flavonoid
luteolin
scaveng
oxygen
radic
inhibit
rhoa
gtpase
prevent
monocyt
infiltr
cn
hendrik
et
al
metallothionein
ii
antioxid
protein
act
antiinflammatori
neuroprotect
espejo
et
al
vitamin
declin
induc
nitric
oxid
synthas
chemokin
monocyt
recruit
cn
stimul
activ
cell
apoptosi
cn
pedersen
et
al
k
channel
blocker
alkoxypsoralen
kaliotoxin
charybdotoxin
bupivacain
anandamid
spermin
ruthenium
red
inhibit
cell
activ
hybrid
peptid
made
integrin
antigen
epitop
plp
glutam
acid
decarboxylas
gad
block
immunolog
synaps
kobayashi
et
al
fulleren
hybrid
molecul
hybrid
molecul
made
antioxid
carboxyfulleren
moieti
nmda
receptortarget
adamantyl
group
inhibit
oxid
injuri
chemokin
express
cell
infiltr
demyelin
axon
loss
basso
et
al
tabl
reproduc
mix
et
al
slight
modif
permiss
publish
springer
